Kumar A, Gangwar R, Zargar AA, et al
In 2023, Pfizer published research papers successively, reporting the results of randomized clinical trials on the efficacy and safety of PF-06882961 for blood sugar control in patients with type 2 diabetes, the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06882961 in Japanese adults with type 2 diabetes from a phase 1 clinical trial, and the results of a 12-week randomized, placebo-controlled, dose-escalation phase 2 trial on the tolerability, safety, and pharmacodynamics of PF-06882961 for the treatment of type 2 diabetes
It's ideal for those who need to bring some extra shine to their complexion without the weight of highlighters
The product marks another step in the brand's expansion beyond condition-specific wellness, reflecting a broader trend of Indian health brands investing in premium formulations and category innovation
The first FDA-approved oral GLP-1 medication as part of weight management care was Wegovy (oral semaglutide), which also has an injectable version